May 08, 2026

Phase 3 Win for TED Therapy

Amgen’s subcutaneous TEPEZZA meets phase 3 endpoints in thyroid eye disease

The Ophthalmologist

May 07, 2026

Seeing ROP Clearly

How AI and XR simulations are transforming training for retinopathy of prematurity

The Ophthalmologist

May 06, 2026

Texas First for Epioxa Therapy

The first US rollout of FDA-approved epi-on cross-linking aims to improve comfort and recovery for keratoconus patients

The Ophthalmologist

May 05, 2026

Early Experience of Superior Efficiency with UNITY® VCS/CS

Four leading surgeons discuss their early experience with Alcon’s UNITY® VCS/CS platform

The Ophthalmologist

May 05, 2026

Is Europe Safe from the Myopia Epidemic?

As global myopia rates soar, three landmark meta-analyses examine the European epidemiological landscape

The Ophthalmologist

May 04, 2026

The Art of Ophthalmology 2026

Showcasing artwork and images from across the spectrum of ophthalmology

The Ophthalmologist

May 04, 2026

Monaco Event Explores Changes in Vision Care

EssilorLuxottica meeting covered advances in AI, diagnostics, and connected eyewear

The Ophthalmologist

May 01, 2026

FARETINA Study Confirms Faricimab Durability

An IRIS Registry analysis presented at ARVO 2026 shows stable vision, durability, and reduced treatment burden across more than 40,000 eyes over 2 years.

Retinal Physician

May 01, 2026

2026 Retina World Congress Preview

Baruch D. Kuppermann, MD, PhD, highlights the global focus and broad retina agenda of the upcoming Retina World Congress meeting in Fort Lauderdale.

Retinal Physician

May 01, 2026

IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial

At ARVO 2026, Arshad M. Khanani, MD, MA, FASRS, presented phase 2 data on vamikibart, an IL-6 inhibitor, in diabetic macular edema.

Retinal Physician